论文部分内容阅读
目的 探讨万爽力(曲美他嗪)对稳定性冠心病患者内皮细胞功能的影响。方法 对61例稳定性冠心病患者采用随机、单盲、对照的方法分为两组,一组为常规治疗组(n=30),另一组为万爽力组(n=31),连续治疗8周。治疗前后静脉抽血,采用放射免疫法测定血浆中的肾上腺髓质素(ADM)及内皮素-1(ET-1)的浓度。结果 万爽力组治疗后ADM浓度明显上升(P<0.05),同时ET-1浓度明显下降(P<0.05),且与常规治疗组比较有显著差异(P<0.05)。结论 万爽力可改善稳定性冠心病中层得内皮细胞功能。
Objective To investigate the effect of Wanzhuangli (trimetazidine) on endothelial cell function in patients with stable coronary heart disease. Methods Sixty-one patients with stable coronary heart disease were randomly divided into two groups: control group (n = 30), Wanxuli group (n = 31), continuous Treatment for 8 weeks. Venous blood was drawn before and after treatment, and the concentrations of adrenomedullin (ADM) and endothelin-1 (ET-1) in plasma were determined by radioimmunoassay. Results The concentration of ADM in Wanshuangli group increased significantly (P <0.05) and the concentration of ET-1 decreased significantly (P <0.05), and there was a significant difference (P <0.05) compared with the conventional treatment group. Conclusion Wanzhuangli can improve the stability of endothelial cells in the middle of coronary heart disease.